FDA Approves Ziftomenib as First Targeted Therapy for (R or R) NPM1+ Acute Myeloid Leukemia

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Metastatic Kidney Cancer

Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer

ESMO’s Road Map for Safe and Effective Use of AI-LLMs in Cancer Care: 23 Rules from 20 Experts

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer

Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival Benefit in Endometrial Carcinoma

AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response

Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

LED-Activated SnOx Nanoflake Therapy Destroy Tumor Cells with Precision

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer

FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer

The VAPOR 2 Trial and the Potential of Water Vapor Ablation in Prostate Cancer Treatment

DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer

Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers

FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer

Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer

Sugary Drinks Drive Colorectal Cancer Metastasis via SORD Pathway, Study Finds

NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer

EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer

Climate-Driven Health Risks to Put $1.5 Trillion in Productivity at Stake by 2050